



PERSONAL INFORMATION

Name Valentina Svicher
Address Department of Biology, University of Rome Tor Vergata
Telephone +39 0672596564 Mobile 3332381462
SCOPUS links <https://www.scopus.com/authid/detail.uri?authorId=8632349900>
Other link
E-mail Valentina.svicher@uniroma2.it
Nationality Italian
Gender F
Codice Fiscale: SVCVNT77C42H501A
ORCID: 0000-0002-2377-504X

PUBLICATIONS

Total number of publications in peer-review journals: **130**
Total number of citations: **2386** (Scopus) **3055** (Google Scholar)
H index: **27** (Scopus) **33** (Google Scholar)
Invited as speaker at >80 National and International Conferences

FIELD OF INTEREST

Her research interests and expertise are on viruses since 2002. She has a consolidated and long-lasting experience in the mechanisms underlying viral cytopathogenicity and interplay with human host. Other research interests include: antiviral drug resistance, efficacy of antiviral drugs in in vitro and in vivo, viral pathogenesis and oncogenesis, viral tropism, viral evolution and dynamics, genotypic (by Sanger and NGS sequencing), structural and functional analysis of viral proteins.

AWARDS

She received several Awards for the presentation of results in National and International Conferences as follows:

Awards received for scientific publications:

1. "GB Rossi" Scientific Award as an Italian researcher distinguished in the field of AIDS research for the best work published in the period from 1 July 2008 to 30 June 2009 (V. Svicher et al., Antimicrob Agents Chemother. 2009).
2. "Readfiles" Scientific Award as an Italian researcher distinguished in the field of AIDS research for the best work published in the period from 1 July 2007 to 30 June 2008 (V. Svicher et al., J Infect Dis. 2008).
3. "GB Rossi" Scientific Award for the best publication in the field of HIV research in the period between 1 July 2007 - 30 June 2008 (second author, F. Ceccherini-Silberstein et al., J. Virol., 2007).
4. Scientific Prize "Infection Lab 2016 - YOUNG INFECTIOLOGISTS IN COMPARISON" for the best scientific project presented in the competition (presenter of the research project and latest author of the related publication (Salpini et al., Oncotarget 2017).

Awards received for presentations of scientific works at national and international conferences:

5.

Award ICAR CROI Award 2021 for young Italian investigators for the oral presentation in the setting of "Conference on Retroviruses and Opportunistic Infections" (CROI) 2021 (senior author of the award-winning presentation)

6. Award for the best oral presentation at the "European Meeting on HIV & Hepatitis 2020" Conference, held in digital version from 28 to 30 October 2020 (last author of the award-winning presentation)

7. Award for the best oral presentation in the context of "Basic Science" at the "International Liver Meeting 2019" promoted by the "European Association for the Study of the Liver" (EASL) (first author of the presentation). The International Liver Congress is one of the main international conferences in the hepatology field

8. SIM 2019 "Francesco Galderi" Award for the best poster in the Virology area, awarded by the Italian Society of Microbiology as part of the 47th National Congress, held in Rome from 18 to 21 September 2019 (last author of the award-winning presentation).

9. Award for the best oral presentation at the "11th Italian Conference on AIDS and Antiviral Research" (2019) (last author of the award-winning presentation)

10. Award for the best oral communication at the congress "4th Italian experience in biomedical research: young minds at work" Desenzano 18-19 November 2016 (last author of the award-winning communication, A Battisti et al., 2016)

11. Best poster award at the 13th EU HIV & Hepatitis Workshop 3-5 June 2015, Barcelona, Spain (latest author of the award-winning poster, A Battisti et al., 2015).

12. Award for the best oral presentation at the 2nd Italian Conference on AIDS and Retroviruses, Brescia, Italy, 20-22 June, 2010 (second author, C. Alteri et al, 2010).

13. Best poster award at the XXXVI AMCLI National Congress, Rimini, Italy, 2-5 October 2007 (co-author, G. Cappiello et al, 2007).

14. Award for the best oral presentation at the 3rd European HIV Drug Resistance Workshop, Athens, Greece, March 30 - April 1, 2005 (first author and presenter of oral communication, V. Svicher et al, 2005).

WORK EXPERIENCE

- Dates (from - to) 2017-today
- Name / address employer University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 - Rome
- Occupation or position held **Associate Professor**

- Dates (from - to) 2012-2017
- Name / address employer University of Rome Tor Vergata, Via Montpellier 1, 00133 - Rome
- Occupation or position held **Assistant Professor**

- Dates (from - to) 2006-2012
- Name / address employer University of Rome Tor Vergata, Via Montpellier 1, 00133 - Rome
- Occupation or position held **Research Fellowship**

EDUCATION AND TRAINING

- Dates (from - to) 2002-2005
- Name organisation training University of Rome Tor Vergata
- Principal subjects Virology
- Title of qualification awarded **PhD in Immunology and Microbiology**

- Dates (from - to) 2004
- Name organisation training Max Planck Institute, Saarbruecken, Germany
- Principal subjects Virology
- Title of qualification awarded **Visiting Research**

- Dates (from - to) 1996-2001
- Name organisation training Sapienza University of Rome

- Principal subjects Neurobiology
- Title of qualification awarded **Degree in Biological Science (110/110 cum laude)**

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE **Italian**
 OTHER LANGUAGES **ENGLISH**

SCIENTIFIC SKILLS AND COMPETENCES Author of >450 scientific articles and abstracts of Conference presentations (including 130 full-length articles in international peer reviewed journals; > 150 abstracts of conferences published in "peer reviewed" journals (> 100 with Impact Factor). Attended at numerous National and International Conferences presenting her work, with more than 80 Invited Lectures, 150 Oral Communications, and 150 Posters, as well as moderator of oral sessions, symposia or poster tours.

RELEVANT ROLES AND COMPETENCES

Coordination and administration of people, projects and budgets.

Member of:

- Board of the Scientific Society "European Society for Antiviral Research (ESAR)"
- HCV Italian Resistance Network Study Group
- HepCare study group (Hepatitis C antiviral therapy failure Registry) promoted by the ESAR Society
- Scientific Committee of ICoNA (Italian Cohort of Naive Antiretrovirals)
- Study Group on therapy and prophylaxis for HBV in haematological patients and stem cell transplant patients. The group involves the following Scientific Societies: SIMIT, SIVIM, SIE, GITMO
- Working group aimed at updating the Italian recommendations on the treatment of chronic hepatitis B which involved the SIMIT and AISF Scientific Societies
- European Consensus Group for the drafting of the European Guidelines for the determination of HIV tropism in clinical practice

Affiliations to scientific associations in progress and over the years

Associazione Italiana per lo Studio del Fegato (AISF) Società Italiana di Virologia (SIV)

Società Italiana di Microbiologia (SIM)

Società Italiana delle Malattie Infettive (SIMIT)

European Association for the Study of the Liver (EASL)

Reviewer for peer reviewed journals: Clinical Microbiology and Infection, PLoS Computational Biology, PLoS One, Journal of Virological Methods, Clinical Microbiology and Infection, Antiviral Research, Journal of Acquired Immunodeficiency Syndromes, AIDS Research and Human Retroviruses, Journal of Antimicrobial Agents and Chemotherapy, Retrovirology, Viruses, Frontiers in Microbiology, Gut, Journal of World Gastroenterology, Journal of World Hepatology, Liver International

20 Relevant Publications:

1. Alkhatib M, Salpini R, Carioti L, Ambrosio FA, D'Anna S, Duca L, Costa G, Bellocchi MC, Piermatteo L, Artese A, Santoro MM, Alcaro S, **Svicher V***, Ceccherini-Silberstein F. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. *Microbiol Spectr*. 2022 Apr 27;10(2):e0273221. * **Corresponding author IF 7.171**
2. Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-Silberstein F, Perno CF, Andreoni M, **Svicher V***, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. *Biomedicines*. 2022 Feb 14;10(2):443. **IF 6.081 * Joint last author**
3. Piermatteo L, Alkhatib M, D'Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, Grelli S, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, **Svicher V**. HBsAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. *Biomedicines*. 2021 Sep 29;9(10):1352. **IF 6.081**

4. **Svicher V**, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. **Gut**. 2021 Dec;70(12):2337-2348. **IF 23.059**
5. Alkhatib M*, **Svicher V***, Salpini R, Ambrosio FA, Bellocchi MC, Carioti L, Piermatteo L, Scutari R, Costa G, Artese A, Alcaro S, Shafer R, Ceccherini-Silberstein F. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. *Microbiol Spectr*. 2021 Dec 22;9(3):e0109621. * **First author equally contributed IF 7.171**
6. Salpini R, Alkhatib M, Costa G, Piermatteo L, Ambrosio FA, Di Maio VC, Scutari R, Duca L, Berno G, Fabeni L, Alcaro S, Ceccherini-Silberstein F, Artese A, **Svicher V**. Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. *J Antimicrob Chemother*. 2021 Jan 19;76(2):396-412. **IF 5.790**
7. Salpini R, Piermatteo L, Battisti A, Colagrossi L, Aragri M, Yu La Rosa K, Bertoli A, Saccomandi P, Lichtner M, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Iapadre N, Cerva C, Aquaro S, Angelico M, Sarmati L, Andreoni M, Verheyen J, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, **Svicher V**. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. *Viruses*. 2020 Feb 23;12(2):251. **IF 5.048**
8. Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, **Svicher V**. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. **Emerg Microbes Infect**. 2020 Dec;9(1):928-939. **IF 7.163**
9. Artese A*, Svicher V*, Costa G, Salpini R, Di Maio VC, Alkhatib M, Ambrosio FA, Santoro MM, Assaraf YG, Alcaro S, Ceccherini-Silberstein F. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. *Drug Resist Updat*. 2020 Dec;53:100721. **First author equally contributed IF 18.5**
10. Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, **Svicher V**. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. **Clin Microbiol Infect**. 2019 Jul;25(7):906.e1-906.e7. **IF 7.117**
11. Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, **Svicher V**. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. **Oncotarget**. 2017 Feb 28;8(9):15704-15715. **IF 5.008**
12. Aragri M, Alteri C, Battisti A, Di Carlo D, Minichini C, Sagnelli C, Bellocchi MC, Pisaturo MA, Starace M, Armenia D, Carioti L, Pollicita M, Salpini R, Sagnelli E, Perno CF, Coppola N, **Svicher V**. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. **J Infect Dis**. 2016 Jun 15;213(12):1897-905. **IF 6.344**
13. Hermans LE*, **Svicher V***, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dydá T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR working group of the European Society for Translational Antiviral Research (ESAR). Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). **J Infect Dis**. 2016 Jan 1;213(1):39-48. **IF 5.99, * equally contributed**
14. Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D'Amore C, Marrone A, Marignani M, Sarrecchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, **Svicher V**. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. **Hepatology**. 2015 Mar;61(3):823-33. **IF 11.19**
15. Pollicita M, Surdo M, Di Santo F, Cortese MF, Fabeni L, Fedele V, Malet I, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Perno CF, **Svicher V**. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. **J Antimicrob Chemother**. 2014 Sep;69(9):2412-9. **IF 5.338**
16. Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Parrotta L, Perno CF, **Svicher V**. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. **Drug Resist Updat**. 2011 Jun;14(3):141-9.

17. I. Lenci, G. Tisone, D. Di Paolo, F. Marcuccilli, L. Tariciotti, M. Ciotti, **V. Svicher**, C.F. Perno, M. Angelico. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. *Journal of Hepatology* (2011) 55(3):587-93. **IF 9.264.**
18. **Svicher V**, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spanò A, Cappiello G, Perno CF. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. *J Hepatol*. 2009 Mar;50(3):461-70. **IF. 7.181**
19. **Svicher V**, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Specific enfuvirtide- associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. *J Infect Dis*. 2008 May 15;197(10):1408-18. **IF. 5.682**
20. **Svicher V**, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. *J Virol*. 2006 Jul;80(14):7186-98. **IF. 5.341**

RELEVANT GRANTS

2022-today: Principal Investigator of the project "Establishment of biomarker assays to support hepatitis B virus (HBV) cure strategies" promoted by Roche Pharma Research & Early Development

2021-today: Collaborator of Partner Unit for the European Project EuCARE "European cohorts of patients and schools to advance response to epidemics" funded through HORIZON-HLTH-2021- CORONA-01, grant agreement No 101046016, lasting 5 years

2019-today: Principal Investigator of Working Unit in the Project "IMMUNO-VIROLOGICAL DYNAMICS triggered by anti-HIV therapy Suspension (IMVIDYS)" granted by the Italian Ministry of Education and Research.

2019-2021 Scientific coordinator of the virological analyzes conducted within the project: "Multi-faceted viral phenotyping and sequencing of chronic hepatitis B patients for disease stratification" led by Prof P. Kennedy at the Barts Liver Center, Immunobiology, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

2018-2019: Principal Investigator of the study "Characterization of HBeAg levels in the natural history of HBV infection and its role in predicting patients' therapeutic outcome and liver disease progression" funded by Diasorin.

2018-2019: Principal Investigator of the study "Characterization of HBsAg and HBeAg levels in the natural history of chronic HBV-HDV infection and their correlation with the kinetics of HBV and HDV replication and the severity of liver disease" funded by Diasorin.

2013-2015: Principal Investigator of the project "From Functional Cure to Reactivation of HBV Infection: Identification and Functional Characterization of Genetic Elements in HBV Genome Correlated with reactivation in the setting of Immunosuppression" as part of the research program "Partnering for Cure research project "Sponsored by Bristol Meyer Squibb.

2012-2018: WP1 Coordinator "Application of full length sequencing methods for the definition of viral genetic markers predictive of persistence and oncogenesis" within the project "Omics Applications in Virology" of the InterOmics Flag Research Project PB05 1 ° "Development of an integrated platform for the application of the" omics "sciences to the definition of biomarkers and diagnostic, predictive and teranostic profiles", financed by the Ministry of University and Research.

2009-2014: Workpackage Deputy 7 under the CHAIN European Research Project, the "Collaborative HIV and Anti-HIV Drug Resistance Network", Integrated Project no. 223131 funded for 5 years by the European Commission Framework 7 Program.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Place and date

Signature

Rome, 28th April 2022

